$AMAT — AVOID 📊 | 6 MONTHS THESIS

$AMAT — AVOID 📊 | 6 MONTHS THESIS 🎯 FQ2 FY2026 (ends Apr) | reported May 14 | Rev $7.9B | EPS $2.86 vs $2.69 🟢 | Margin 31.9% 💡 Consensus expects sustained high-single-digit revenue growth and stable margins, but market-implied valuation already discounts perfection. The variant view is that recent earnings beats and strong guidance are fully priced in, and any cyclical softening or margin pressure could trigger a sharp de-rating, creating a negatively skewed setup. 📉 Reward/risk: 0.27:1 🏢 Business Quality: 9/10 - Dominant moat in deposition and etch, high margins (49.9% gross, 31.9% operating), robust cash generation, secular tailwinds, but cyclical exposure. 📊 Valuation: rich - Trading at 46.8x trailing P/E, ~40x forward P/E, EV/EBITDA ~45x, and FCF yield ~2.6%, all well above peer median (19.7x) and broad historical... 📊 Our read: AVOID. Full analysis → https://stockduty.xyz/s/AMAT0612

🎯 FQ2 FY2026 (ends Apr) | reported May 14 | Rev $7.9B | EPS $2.86 vs $2.69 🟢 | Margin 31.9%